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Abstract
Medulloblastoma (MB) is the most common malignant brain tumor in childhood and
represents the main cause of cancer-related death in this age group. The phosphoinositide
3-kinase (PI3K) pathway has been shown to play an important role in the regulation of
medulloblastoma cell survival and proliferation, but the molecular mechanisms and
downstream effectors underlying PI3K signaling still remain elusive. The impact of RNA in-
terference (RNAi)-mediated silencing of PI3K isoforms p110α and p110δ on global gene ex-
pression was investigated by DNAmicroarray analysis in medulloblastoma cell lines. A
subset of genes with selectively altered expression upon p110α silencing in comparison to
silencing of the closely related p110δ isoform was revealed. Among these genes, the leuke-
mia inhibitory factor receptor α (LIFR α) was validated as a novel p110α target in medullo-
blastoma. A network involving c-Myc and miR-125b was shown to be involved in the control
of LIFRα expression downstream of p110α. Targeting the LIFRα by RNAi, or by using neu-
tralizing reagents impaired medulloblastoma cell proliferation in vitro and induced a tumor
volume reduction in vivo. An analysis of primary tumors revealed that LIFRα and p110α ex-
pression were elevated in the sonic hedgehog (SHH) subgroup of medulloblastoma, indicat-
ing its clinical relevance. Together, these data reveal a novel molecular signaling network,
in which PI3K isoform p110α controls the expression of LIFRα via c-Myc and miR-125b to
promote MB cell proliferation.
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Introduction
Medulloblastoma is the most common malignant brain tumor in children and accounts for
approximately 20% to 25% of all pediatric central nervous system tumors [1, 2]. Most medullo-
blastoma occur between 5 and 10 years of age [1, 3]. The standard treatment of medulloblasto-
ma involves surgery followed by chemotherapy and, in the case of children older than 3–
5 years, craniospinal radiotherapy [3]. However, nearly half of all patients die from progressive
disease and the 5-year survival rate is below 50% for high-risk patients [2]. There is an urgent
need to develop novel targeted therapeutic approaches for medulloblastoma, which will origi-
nate from a better understanding of the disease biology.
Medulloblastoma has been recognized to be a heterogeneous disease, and no recurrent can-
cer gene mutations have been found, although many of the mutations described so far affect
key intracellular signaling pathways, such as sonic hedgehog (SHH) and Wnt/β-catenin [4, 5].
Genomic studies in large series of primary medulloblastoma have led to a novel classification
of medulloblastoma into different molecular subtypes, characterized by the activation of sonic
hedgehog (SHH), Wnt/ β-catenin or c-Myc pathways (Group 3) [5]. c-Myc plays an important
role in medulloblastoma biology and therefore targeting the signaling networks controlled by
c-Myc may be a promising approach to develop targeted therapies for the subsets of tumors in
which c-Myc is activated [6–11].
Another signaling pathway which is being considered to develop targeted therapies for me-
dulloblastoma, is the receptor tyrosine kinase (RTK) cascade, which links polypeptide growth
factors to cellular responses via their downstream signaling intermediates, in particular phos-
phoinositide 3-kinase (PI3K), Akt, the mammalian target of rapamycin (mTOR) and mitogen-
activated extracellular signal-regulated kinase activating kinase (MEK) [12–18].
The PI3K signaling pathway controls key cellular responses, such as cell growth and prolif-
eration, survival, migration and metabolism. Over the last decades, it has been recognized that
this intracellular signaling pathway is frequently activated by genetic and epigenetic alterations
in human cancer, including malignant brain tumors [4, 15, 19, 20]. The PI3K family of signal-
ing enzymes comprises eight catalytic isoforms, which are subdivided into three classes. The
class IA PI3K isoform p110α is considered to be a validated drug target in human cancer, in
particular because activating mutations in the PIK3CA frequently occur in human cancer [21,
22]. In medulloblastoma, the PIK3CA gene is targeted by mutations at a low frequency [23],
but the p110α isoform is also over-expressed in primary tumors and cell lines [15]. Our previ-
ous studies demonstrate the distinct roles of the class IA PI3K isoforms in medulloblastoma,
from which p110α showed the strongest effects in the control of medulloblastoma prolifera-
tion, survival and chemoresistance. Targeting p110α by RNAi or isoform-specific inhibitors
impaired medulloblastoma cell proliferation, survival and chemoresistance, while similar ef-
fects were not observed for p110δ. However, co-targeting of p110α and p110δ led to increased
effects on medulloblastoma cell proliferation [15].
Clinical trials have started to evaluate the safety and efficacy of agents targeting this pathway
in different brain tumors including medulloblastoma [19]. However, targeting the PI3K path-
way remains challenging. Thus, the effort of characterizing the molecular mechanisms and the
PI3K downstream effectors in MB will contribute to the elucidation of how PI3K drives onco-
genic signaling and may lead to the identification of PI3K target genes as novel candidates for
targeted therapy in MB.
Here, we performed a genomic study to compare the changes in the global gene expression
profiles of medulloblastoma cells caused by RNAi-mediated down-regulation of p110α or
p110δ. Among both PIK3CA and PIK3CD responsive genes, we identified c-Myc as the tran-
scription factor, whose network of genes was mostly deregulated. Intriguingly, the c-Myc
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network included the α-subunit of the receptor for the leukemia inhibitory factor (LIFRα). Our
data describe, for the first time, a signaling network in which c-Myc controls the expression of
LIFRα, in part through the regulation of miR-125b, to contribute to oncogenic p110α signaling
in medulloblastoma.
Materials and Methods
Cell culture and treatments
The MB cell lines were obtained and cultured as described in [15], the stable clones DAOY
V11 (empty vector transfected) and DAOYM2.1 (MYC vector transfected) were described in
[24, 25]. PFSK and PNET5 medulloblastoma cell lines were purchased from the American
Type Culture Collection and were grown in RPMI 1640 with 10% FCS and penicillin/strepto-
mycin/L-glutamine (Sigma, Buchs, Switzerland). D341 and D458 were a kind gift of Dr. Henry
Friedman (Duke University, Durham, NC) [26] and were cultured in Improved MEMmedium
(Invitrogen, Carlsbad, CA, USA) supplemented with 1% L-glutamine, 1% Penicillin/Strepto-
mycin, 10% FCS. The UW228 cells expressing tamoxifen-inducible c-Myc-ER were kindly pro-
vided by Prof. Annie Huang, Hospital for Sick Children, Toronto, Canada and described in
[27]. All cells were grown in a humidified atmosphere at 37° and 5% CO2. Tamoxifen (Sigma)
was used to induce c-Myc expression in these clones. The PI3K inhibitors PIK75 and YM024
(Calbiochem, Darmstadt, Germany) were dissolved in DMSO (Sigma) at 10 mM and diluted to
the indicated concentrations in cell culture medium just before use. The Anti-human LIFRα
antibody (AF-249-NA) and the recombinant rh-LIF Rα (7487-LR) were purchased from R&D
Systems (Minneapolis, MN, USA) and were diluted directly into the medium immediately be-
fore use. For growth factor stimulations, cells were grown to confluence, starved overnight in
culture medium containing 1% FCS. Cells were maintained in serum-free RPMI for 1 h and
were then stimulated with LIF (Sigma, Buchs, Switzerland) for 10 min.
RNA interference and miRNA transfection
MB cell lines were transfected with siRNA pools, each comprising four individual oligonucleo-
tides (SMARTpool small interfering RNA reagents; Dharmacon, Waltham, MA, USA),
directed against PIK3CA (M-003018-0), PIK3CD (M-006775-02-0005),MYC (M-003282-07),
LIFR (M-008017-01-0005) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) as di-
rected by the manufacturer for adherent cell lines. siCONTROL Non-targeting siRNA Pool
(D-001206-14-20) (Dharmacon) composed of four siCONTROL Non-targeting siRNAs was
used as negative control. All siRNAs were used at a final concentration of 20 nM. Cells were in-
cubated for 24 h to 48 h and after mRNA and protein were extracted to assess protein expres-
sion by Western blotting and mRNA expression by TaqMan analysis.
DAOY cells were transfected with 20nM of miRIDAN hairpin inhibitor directed against
mature hsa-miR-125b, 20 nM of precursor for hsa-miR-125b-5p or with Hairpin Negative
Control (Thermo Fisher Scientific, Waltham, MA, USA) using SilentFect (Biorad, Hercules,
CA, USA) as suggested by the manufacturer. Protein and mRNA were extracted and analyzed
after 48h.
Plasmid transfections
DAOY cells were transfected with expression plasmids using the Lipofectamine Plus reagent
(Invitrogen) according to the manufacturer's recommended protocol. The plasmids encoding
for activated PI3K-p110α (PIK3CA CAAX) and pcDNA3 (empty vector control) were de-
scribed in [28].
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Microarray analysis
The cDNA microarray analysis was performed in collaboration with the Functional Genomic
Center of the University Zurich, Switzerland. Human Genome-U133 Plus 2.0 Affymetrix Gen-
eChips arrays (Affymetrix, Santa Clara, CA, USA) were used to assess the gene expression data.
Raw data generated by the GCOS Software (Affymetrix) were processed by using the RMA
method [29] and further statistically analyzed by using the software R and applying Student’s
t-test.
Each experiment represented a group of three independent biological replicates. Results are
expressed as fold change, and differences in expression were considered significant if the fold
change was> 2.0 or<-2 and the P-value< 0.001. Comparative and cluster analysis of the data
were performed using the softwares Cluster 3.0 and TreeView [30]. The GeneGOMetaCore
(GeneGO, St Joseph, MI, USA) was used to identify affected pathways and networks of genes,
according to their ontological categories. The data was deposited in the Gene Expression Om-
nibus and is accessible through GEO series accession number GSE40564 (http://www.ncbi.
nlm.nih.gov/geo).
Gene expression analysis
Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Basel, Switzerland) and con-
verted into cDNA using High-Capacity cDNA Reverse Transcription Kit according to manu-
facturer's instructions (Applied Biosystems, Foster City, CA, USA). Assays-on-Demand Gene
Expression products (Applied Biosystems) were used to measure mRNA expression levels of
PIK3CA (Hs00907965_m1), PIK3CD (Hs00192399_m1),MYC (Hs00153408_m1), LIFR
(Hs00158730_m1) and GAPDH (Hs99999905_m1; internal control gene). Relative mRNA
expression levels were calculated using the comparative threshold cycle (CT) method.
The miRNAs extraction procedure via RNeasy Mini Kit (Qiagen, Basel, Switzerland) was
followed by specific reverse transcription and amplification using hsa-miR-125b (000449) and
U6 snRna (001973; loading control). Relative miRNA expression levels were calculated using
the comparative threshold cycle (CT) method.
For semi-quantitative analysis of the gene expression, the One-Step RT-PCR Kit (Qiagen)
was employed. The primers for LIF, LIFR and GAPDH were purchased from Microsynth (Bal-
gach, Switzerland). DNA was separated on 2.5% agarose gel and stained with GelRed (Biotium,
Hayward, CA, USA).
The expression data of medulloblastoma (n = 62) which are available from NCBI’s Gene Ex-
pression Omnibus (http://www.ncbi.nlm.nih.gov/geo/; accession number GSE10327) pub-
lished by Kool et al., [31] and expression data of a second cohort of medulloblastoma (n = 103;
available from NCBI’s Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/; acces-
sion number GSE21140, reported by Northcott et al. [32]) were used for analysis. Data are ac-
cessible through the open access database R2 for visualization and analysis of microarray data
(http://r2.amc.nl), and data were generated using the R2 microarray analysis and visualization
platform (http://r2.amc.nl). Gene expression levels were compared using the Kruskal-Wallis
test. If this global test was significant, Dunn's post hoc tests were used to compare the groups.
Western blotting
Cell lysates were prepared in RIPA buffer (50mM Tris-Cl, [pH 6.8], 100mM NaCl, 1% w/v Tri-
ton X-100, 0.1% w/v SDS) supplemented with Complete Mini Protease Inhibitor Cocktail
(Roche Applied Sciences, Germany) and with the phosphatase inhibitors β-glycerophosphate
(20mM) and Na3VO4 (200 mM). Proteins were separated by SDS–polyacrylamide gel electro-
phoresis and transferred on hydrophobic polyvinylidene difluoride (PVDF) membrane
PI3K Signaling Controls LIFR in Medulloblastoma
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(Amersham, GE Healthcare, UK). Antibodies specific for PI3K p110α (sc-1331), p110δ (sc-
136032), c-Myc (sc-789), LIFR (sc-659), Akt1/2/3 (sc-8312), ERK 1/2 (sc-99) (Santa Cruz
Biotechnology, CA, USA) were diluted 1/500 in 5% BSA, phospho-ERK1/2 (Thr202/Tyr204)
(cs-4370), phospho-Akt (Ser473; Thr308) (cs-3787; cs-2965), phospho-S6 (Ser235/236,
Ser240/244) (cs-2211; sc-5364) (Cell Signaling Technology, Inc., Danvers, MA, USA), β-actin
(Sigma-Aldrich Chemie GmbH, Buchs, Switzerland) (A5441) were diluted 1/1000 in 5% BSA.
Chemiluminescence was used for detection using SuperSignal West Femto Maximum Sensitiv-
ity Substrate (Thermo Fisher Scientific Inc., Rockford, IL, USA).
Cell proliferation assays
Cell proliferation was assessed using the Cell Titer 96 Aqueous Cell Proliferation Assay (Pro-
mega, Madison, WI, USA). Data are expressed as average values from at least three
independent experiments.
Chicken chorioallantoic membrane assay
Fertilized chicken eggs (gallus gallus) purchased from a local hatchery were incubated in a hu-
midified incubator at 37°C. On embryonic day 3, a squared opening was excised into the shell
and sealed with tape. Upon 96h of incubation, a silicon ring was placed on the chorioallantoic
membrane and after gentle a scraping, a suspension of 5 million DAOY cells in 20ml phos-
phate-buffered saline was applied onto the lacerated membrane. On embryonal day 10, the
formed tumors were treated with either rh-LIFα (Recombinant Human LIFRα, R&D Systems,
Minneapolis, USA, catalog number 7487-LR) or phosphate-buffered saline for 4 consecutive
days. On embryonal day 14, tumor volume was measured, as described in [33] and the embryos
were sacrificed.
ChIP-on-chip
ChIP-on-chip experiments using a MYC antibody were performed as previously described [24,
34].
Ethics statement
All the experiments were performed in conformity with the Swiss animal protection law, re-
quiring no specific approval for working on avian embryos before day 15 of their embryonal
development. Thus, on day 14, the experiments were terminated by arterial excision.
Statistical analysis
All experiments were performed at least in triplicates. Data are represented as mean ± SD. The
statistical significance of differences between groups was assessed with ANOVA using Tukey’s
post hoc tests calculated with the statistical software GraphPad PRISM 5 (GraphPad Software,
San Diego, CA, USA); P-Values of<0.05 were considered significant and indicated with a sin-
gle asterisk, a double asterisk if P<0.001 or a triple asterisk if P<0.001. All statistical analyses
were intended to be rather exploratory than confirmatory and nominal p-values are reported,
without adjustment for multiple testing.
Distribution of gene expression levels were compared using the Kruskal-Wallis test. P-
values< 0.05, two-tailed were considered statistically significant. Statistical analyses were per-
formed using GraphPad Prism 4 (GraphPad Software, San Diego, CA, USA).
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Results
Gene expression analysis reveals selective gene subsets regulated by
p110α
In order to investigate how the class IA PI3K isoforms p110α and p110δ regulate the expression
of specific gene subsets in medulloblastoma, we performed cDNA microarray analysis in
DAOY cells transiently transfected with either siRNA targeting p110α, p110δ or control
siRNA (Fig 1B). The efficacy of the down-regulation of the target proteins by the respective
siRNAs was demonstrated by Western blot analysis, as well as quantitative real time PCR 48h
post transfection (Fig 1A). Thus at 48h post transfection, the most efficient target down-regula-
tion was observed and it was therefore chosen for the cDNA microarray analysis. Each experi-
ment was performed in three independent biological replicates, where the results were
Fig 1. Gene expression analysis. (a) DAOY cells were transfected with siRNA against PIK3CA or PIK3CD and analyzed 48h post transfection for gene
down-regulation at mRNA level by real-time PCR and at protein level by Western blot. (b) Heat map representing the expression of PIK3CA and PIK3CD
regulated genes. (c) GeneGo Metacore analysis of transcriptional networks. The set of genes deregulated by PIK3CA silencing in DAOY cells were analyzed
via GeneGoMetacore software. The most affected network comprising the oncogene c-Myc and some its downstream targets is shown.
doi:10.1371/journal.pone.0123958.g001
PI3K Signaling Controls LIFR in Medulloblastoma
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normalized to the control values and expressed as fold changes. To define lists of differentially
expressed genes, we considered significant those whose fold change was> 2.0 or<-2 and the
P-value< 0.001. Silencing p110α significantly affected the expression of 453 genes, while si-
lencing p110δ resulted in significant changes in 305 genes, showing that p110α has an overall
higher impact on the regulation of global gene expression in MB. In addition, 75 genes were
commonly regulated by both p110α and p110δ (S1 and S2 Tables). The resulting sets of differ-
entially expressed genes were further analyzed using different bioinformatics tools, in order to
establish functional networks and identify relevant targets for validation.
Silencing of p110α perturbs multiple transcriptional networks in
medulloblastoma
To gain insight into the transcriptional networks affected by silencing of p110α and p110δ in
medulloblastoma cells, we performed a biostatistics analysis of the gene expression data with
GeneGOMetaCore. The software was used to define functional annotations for the selected
players, thus assigning them to ontologic categories for association with relevant biologic pro-
cesses and pathways. The transcriptional networks that were most significantly altered by the
down-regulation of p110α and p110δ comprised c-Myc, the estrogen receptor (ER), p53 and
STAT3 (S3 Table). The transcriptional network involving c-Myc included the LIFRα as a target
gene (Fig 1C). LIFRα was found to be more significantly down-regulated in DAOY cells trans-
fected with p110α siRNA, than in the case of p110δ siRNA (Fig 1B and S4 Table), suggesting
that it is selectively regulated by p110α.
Interestingly, STAT3, a downstream target of LIFR was identified as one of the most signifi-
cantly altered networks (S3 Table). Thus, down-regulation of p110α perturbs multiple tran-
scriptional networks in medulloblastoma cells, most notably c-Myc, which is potentially
involved in controlling LIFRα expression [35].
PI3K-p110α dependent regulation of LIFRα expression
In order to validate the LIFRα as a bona fide target of p110α in medulloblastoma cell lines, we
first used quantitative real time PCR and Western blot analysis to confirm the results obtained
from the DNAmicroarrays. Down-regulation of the expression of the LIFRα could indeed be
demonstrated at mRNA and protein level upon selective silencing of p110α, but not p110δ
(Fig 2A and 2B and S3 Table). We next sought to investigate whether pharmacological inhibi-
tion of p110α also reduced LIFRα expression levels in medulloblastoma cell lines. YM024 and
PIK75, two selective p110α inhibitors effectively reduced the expression levels of the receptor
(Fig 2C and Fig 3A). The levels of LIFRα down-regulation achieved by treatment of DAOY
with a low dose (5 μM) of YM024 were comparable to the response observed upon p110α si-
lencing by siRNA (Fig 1 and Fig 2A–2C) and upon PIK75 (100 nM) exposure (Fig 3A and 3C).
To further confirm these observations, DAOY cells were transiently transfected with active
PIK3CA coupled with carboxy-terminal farnesylation signal allowing its localization to the
membrane. Increase of p110α induced a post transcriptional up-regulation of LIFRα expres-
sion leading to activation of LIFRα downstream target, S6 (Fig 2D,2E and 2F). Collectively,
these results confirm that p110α controls the expression of the LIFRα in medulloblastoma
cell lines.
Regulation of LIFR by c-Myc downstream of p110α
We next aimed to analyze the mechanism by which p110α regulates LIFRα expression. Ac-
cording to the analysis of transcriptional networks performed with GeneGo, c-Myc controls a
network of genes comprising LIFRα (Fig 1C). To validate this network, we first analyzed the
PI3K Signaling Controls LIFR in Medulloblastoma
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expression of LIFRα and c-Myc upon inhibition of p110α with PIK75 in a DAOY-derived cell
clone, which over-expresses c-Myc. A strong inhibition of the expression of both proteins was
observed upon PI3K inhibitor treatment (Fig 3A). In addition, we used the MB cell line
UW228-MycER which expresses a fusion protein comprising c-Myc and the hormone-binding
domain of the estrogen receptor (ER) and can be induced by tamoxifen. We observed that
LIFRα expression was induced in a time-dependent manner, which paralleled with the induc-
tion of c-Myc expression (Fig 3B), previously described as a consequence of general increase in
protein synthesis upon tamoxifen treatment [27, 36].
To further investigate p110α—c-Myc-dependent regulation of LIFRα, we performed simul-
taneous or alternate inhibition of p110α (with PIK75) and induction of c-Myc (with tamoxi-
fen). An impaired c-Myc-dependent rescue of LIFRα protein expression was observed
Fig 2. PI3K-p110α dependent regulation of LIFRα expression. Expression of LIFRα was analyzed in DAOY cells transfected with siRNA against PIK3CA
or PIK3CD (a), at protein level by Western blot and (b) at mRNA level by RT-PCR after 48h transfection. Protein and mRNA expression of LIFRα was also
measured upon 24h treatment with YM024 (5 μM). The expression of PI3K-p110α, total and phospho-S6 (Ser235-236) are also shown (c). pcDNA3 vector
containing active PI3K-p110α (PIK3CA CAAX) or not were transfected into DAOY cells. 48h post transfection samples were analyzed for p110α and LIFRα
expression by qPCR (d-e) or Western blot (f). The expression levels of total and phospho-S6 (Ser240/244) were also measured (c-f). (a, c, f) were quantified
by ImageJ analysing software.
doi:10.1371/journal.pone.0123958.g002
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(Fig 3C). Interestingly, at transcriptional level, a partial rescue of the cytokine receptor was ob-
served after 24h of PIK-75 exposure followed by 24h of c-Myc induction (Fig 3C). Together
these results confirm the functionality of the gene network identified by bioinformatic analysis
and describe a role for c-Myc as a regulator of LIFRα expression in MB cell lines.
Fig 3. p110α regulates LIFR expression through c-Myc. The protein expression levels of c-Myc and LIFRαwere evaluated after 12h, 24h and 30h of
100nM PIK75 exposure byWestern blot (a) in DAOY-derived cell clones overexpressing c-Myc (DAOYM2.1) and (b) in UW228-Myc-ER cells induced for c-
Myc expression by tamoxifen for 24 h, 48 h and 72 h. (c) LIFRαmRNA levels were analyzed by qPCR and protein levels were analyzed byWestern blot in the
inducible UW228-Myc-ER cells treated independently, simultaneously or in alternate manner with the p110α inhibitor PIK75 (100 nM) and/or with tamoxifen
(500 nM) for 24 h or 48 h. UW228-Myc-ER were simultaneously exposed to both drugs for 24h (bar 4/lane 4), alternately for 48 h, bar 4/lane 4 24 h tamoxifen
(500 nM) exposure followed by 24 h PIK75 (100 nM) and bar 5/lane5 24 h PIK75 (100 nM) treatment followed by 24h tamoxifen (500 nM) induction.
doi:10.1371/journal.pone.0123958.g003
PI3K Signaling Controls LIFR in Medulloblastoma
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c-Myc dependent inhibition of miR-125b controls LIFRα expression
To elucidate the mechanism of the c-Myc-dependent regulation of the LIFRα, we first per-
formed mRNA and protein expression analysis of LIFRα upon c-Myc silencing using the
DAOYMB cell line over-expressing the oncogene. Silencing c-Myc induced a decrease in
LIFRα protein and mRNA expression level (Fig 4B). Next, we hypothesized whether c-Myc
regulates transcriptionally the expression of LIFRα by directly binding to its promoter. Possible
binding sites of c-Myc on the LIFR promoter sequence were investigated using the software
Genomatix. More than 40 possibilities were found (data not shown), providing a hint that c-
Myc may bind to the promoter of LIFR also in medulloblastoma. However, using ChIP-on-
chip analysis [24], we were unable to confirm a direct binding of c-Myc to the promoter of the
LIFR (data not shown). Since c-Myc is well known miRNA regulator in medulloblastoma [37]
Fig 4. c-Myc regulates LIFR expression via miR-125b. Expression of c-Myc (a) and LIFRα (b) were analyzed by qPCR andWestern Blot in DAOYM2.1
cells, overexpressing c-Myc, transfected with siRNA against c-Myc. (c) miR-125b expression levels were measured by qPCR after 24h and 48h of 4-OHT
treatment in UW228-Myc-ER cells. MiR-125b fold change was calculated via normalization to U6 snRNA expression levels in the corresponding condition (d)
miR-125b expression was analyzed by qPCR after transfection with mimic or antagomir for miR-125b in DAOY cells. MiR-125b fold change was calculated
as in (c) (e) LIFRα expression level was analyzed by qPCR andWestern blot after transfection with mimic or antagomir for miR-125b. (b) and (e) were
quantified by ImageJ analysis software.
doi:10.1371/journal.pone.0123958.g004
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and to this date LIFRα transcriptional regulation is very poorly studied we hypothesized, a c-
Myc-dependent indirect control of LIFR expression via miRNA. Recent studies have described
an auto-regulatory loop connecting the microRNA precursor of the let-7 family with c-Myc.
The oncogene transcriptionally regulates the expression of the let-7 family members, which in
turn regulate c-Myc post-transcriptionally [38]. Using the UW228 medulloblastoma cell line,
expressing inducible c-Myc, we could show a significant decrease in miR-125b (a member of
the let-7 family) expression upon c-Myc induction (Fig 4C). Interestingly, another group has
recently revealed that miR-125a, a miR-125b homologue, directly binds to the LIFRα 3`-UTR
and inhibits its protein and mRNA expression [39, 40]. To assess the impact of miR-125b on
LIFRα expression, DAOY cells were transiently transfected with the corresponding pre- or
anti-miR. mRNA and protein analysis revealed miR-125b-dependent post transcriptional regu-
lation of the receptor (Fig 4E). These results confirm the c-Myc-induced positive loop regulat-
ing LIFRα expression via inhibition of miR-125b.
Expression of LIFRα and LIF in medulloblastoma
Our previous work had documented an over-expression of p110α in primary medulloblastoma,
as well as in medulloblastoma cell lines [15]. Therefore, we hypothesized that the LIFRαmay
also be over-expressed in primary medulloblastoma. A panel of medulloblastoma lines was
screened for LIFRα expression by Western blot analysis, and increased expression of the cyto-
kine receptor was observed in all cell lines when compared to normal brain (Fig 5A). PNET5
and UW228 presented the most increased LIFRα expression level among the MB cell lines. The
expression analysis at mRNA level showed that 4 out of 7 cell lines expressed detectable levels
of LIFRαmRNA (Fig 5B).
We next sought to investigate whether LIFRα was co-expressed with its ligand LIF in MB
cell lines. Three cell lines (DAOY, UW228 and PFSK) co-expressed both the ligand and the re-
ceptor (Fig 5A and 5B), indicating the presence of an autocrine loop in a subset of medulloblas-
toma cell lines.
In order to investigate the clinical relevance of LIFRα, its expression was also analyzed in
the cancer microarray database Oncomine [41]. Data obtained from a published study by
Pomeroy et al. [42] which compared gene expression profiles of different cohorts of classic and
desmoplastic medulloblastomas, supratentorial primitive neuroectodermal tumor, atypical ter-
atoid/rhabdoid tumor and glioblastoma vs. normal cerebellum, showed that the LIFR was
over-expressed in classic medulloblastoma, demosplastic medulloblastoma and in glioblastoma
when compared to normal cerebellum. (S1 Fig).
Next, we investigated the expression levels of PIK3CA and LIFR in two primary medullo-
blastoma cohorts published by Kool et al. [31] and Northcott et al. [32]. LIFR presented lower
expression levels in group WNT and Group 3, while in SHH and Group 4 LIFR displayed
higher expression levels. This unique expression was confirmed in both medulloblastoma co-
horts [31, 32]. The non-WNT tumors (group SHH, group 3 and 4) were characterized by high-
est PIK3CA expression in comparison to patients with good prognosis (groupWNT)
presenting lower PIK3CA expression (Fig 4C). PIK3CA and LIFR expressions correlated exclu-
sively in the WNT and SHH subgroups, lower and higher expression correspondingly (Fig 5C
and S2 Fig).
To further investigate the impact of LIFR expression in medulloblastoma tumors, we com-
pared two cDNA microarray data performed on heterozygous for Patched receptor mice, ex-
pressing wild type or single copy of TP53 [43, 44]. Interestingly, in the SHHMBmimicking
murine model (PTCH-/+, TP53 -/+), LIFR expression was significantly higher, confirming the
role of the cytokine receptor in these tumors (Fig 5D and S3 Fig).
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LIFRα activation stimulates multiple intracellular signaling pathways in
medulloblastoma
In order to investigate whether the LIFRα is functional in medulloblastoma cell lines, we ana-
lyzed the activation status of downstream signaling pathways in response to cell stimulation
with LIF. Dose-dependent activation of ERK and AKT pathways, leading to activation via
phosphorylation of their downstream target S6 was detected, starting at a concentration of LIF
Fig 5. Expression of LIFRα and LIF in medulloblastoma cell lines and primary brain tumors. (a) LIFRα protein levels in medulloblastoma cell lines and
normal brain (NB) tissue were evaluated byWestern blot and compared with β-actin as the loading control. (b) LIF and LIFR expression in medulloblastoma cell
lines was analyzed by semi quantitative RT-PCR. (c) Expression of PIK3CA and LIFR derived from the transcriptomic analysis of primary medulloblastoma,
grouped according to molecular disease variants. Data from Northcott et al [32] are shown. Gene expression levels were compared using the Kruskal-Wallis test
and the p-value is shown at the bottom right of the illustration. As this global test was significant, Dunn's post hoc tests were used to compare the groups. P-
values < 0,05, as determined by Dunn's post hoc tests, are indicated in order to illustrate the differences. (d) Analysis of cDNAmicroarray data performed on
PTCH1+/-; TP53+/- or PTCH1+/-; TP53+/+mice. The table represents a summary of fold change (logFC), average expression values (AveExpr), p values
obtained by comparison of the two murine strains fromData set GEO accession number GSE37316). (e) Cell lysates of DAOY cells stimulated with or not with 5,
10, 25, 50 and 100 ng/ml of LIF for 10min were analyzed for expression and phosphorylation of AKT and ERK pathway downstream targets. Treatment of 10
ng/ml of OSM for 10min was used as a positive control.
doi:10.1371/journal.pone.0123958.g005
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of 5ng/ml and with a maximal effect at 100ng/ml in DAOY cells (Fig 5E). Furthermore, activa-
tion of downstream signaling pathways in response to cell stimulation with oncostatin M
(OSM), a potent activator of LIFR signaling confirmed our data (Fig 5E and S4 Fig). In view of
the activation of these classical downstream signaling pathways, it can be concluded that the
LIFRα is indeed functional in medulloblastoma cell lines.
Targeting LIFRα signaling in medulloblastoma
The role of LIFRα in the control of medulloblastoma cell proliferation and survival was investi-
gated by RNAi downregulation and pharmacological inhibition with a neutralizing antibody
against the receptor and subsequent analysis of MB cell responses. We first used siRNA to tran-
siently down-regulate the expression of the LIFRα in medulloblastoma cell lines (Fig 6A).
Down-regulation of the cytokine receptor led to significantly decreased cell proliferation in
DAOY and UW228 cell lines (Fig 6B).
Fig 6. Effects of LIFRα down-regulation onmedulloblastoma cell proliferation and survival. (a) Protein expression level of LIFRα in DAOY cells
transfected with siRNA against LIFR compared to the control siRNA transfected cells. (b) The effects on cell viability of the siRNA-mediated target down-
regulation of LIFRα (white bars) compared to control siRNA (black bars) in DAOY and UW228 cells was assessed for the indicated time points and
expressed as percentages. (c) The protein expression of LIFRα downstream targets was analyzed upon treatment for 10 or 30 min with 20μg/ml of anti-
LIFRα neutralizing antibody. β-actin was used as a loading control. (d) Cell viability was evaluated in DAOY, UW228, PNET5 and PFSK cells treated for 48h
with an anti-LIFRα neutralizing antibody at the indicated concentrations.
doi:10.1371/journal.pone.0123958.g006
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Furthermore, we analyzed the effect of the cytokine receptor inhibition on the downstream
targets of the signaling pathway. Time-dependent inhibition of ERK and AKT pathways, lead-
ing to decreased phosphorylation of their downstream target the ribosomal protein S6, was
measured upon treatment of 20μg/ml of LIFRα neutralizing antibody in DAOY cells (Fig 6C).
This indicates that the neutralizing antibody disrupts LIF/LIFRα signaling. Similar results were
obtained when using a recombinant human soluble LIFRα as a neutralizing reagent (Fig 7B).
These results were confirmed in 4 MB cell lines, where upon exposure to LIFRα neutralizing
antibody, a significant decrease in cell proliferation was observed (Fig 6D).
In order to explore the therapeutic potential of LIFRα inhibition in vivo, we performed a
chicken embryo chorioallantoic membrane assay (CAM). Direct application of DAOY cells
onto the chorioallantoic membrane led to the formation of solid tumors within 3 days. For the
following 4 days, the tumors were treated with 20μg/mL of recombinant human soluble LIFRα
as a neutralizing reagent (ligand trap) and their volume was compared to a control treatment.
As expected, a significant reduction in the tumor volume was observed upon inhibition of LIF/
LIFRα (Fig 7A). Confirmation of the efficacy of the recombinant human soluble LIFRα, was
observed in DAOY cells treated for 10, 30 and 240 minutes with 20μg/mL of the neutralizing
reagent. As expected, similarly to LIFRα neutralizing antibody, the recombinant human LIFRα
inhibited the AKT and ERK pathways leading to decreased phosphorylation of the ribosomal
protein S6 (Fig 7B). Together these findings confirm the key involvement of LIFRα in medullo-
blastoma tumorigenesis.
Discussion
The PI3K/Akt pathway has been demonstrated to play a key role in medulloblastoma cell pro-
liferation, survival, chemoresistance and migration [4, 11, 15, 16, 45, 46]. Mutations in PIK3CA
were reported in primary medulloblastoma [23], as well as increased expression of PIK3CA at
the mRNA and protein level [15]. Isoform-specific or broad specificity PI3K inhibitors have
shown anti-tumor activity in medulloblastoma models in vitro and in vivo [4, 15, 16]. In gener-
al, these agents reduced the activation status of classical PI3K downstream targets, such as Akt,
mTOR, S6K or GSK-3β.
Fig 7. LIFRα inhibition induces reduction in Medulloblastoma tumor volume. (a) Tumors formed on (CAM) were treated with 20μg/ml of rh-LIFα
recombinant or phosphate-buffered saline for 4 consecutive days. Quantification of tumor volume changes before and after treatment is shown. Lines
indicate the mean of each group, *P<0.05 compared with control treatment. (b) The expression of LIFRα downstream targets was analyzed upon treatment
for 10, 30, 240 min with 20 μg/ml of rh-LIFRα. β-actin was used as a loading control.
doi:10.1371/journal.pone.0123958.g007
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Targeting p110α by RNAi or isoform-specific inhibitors had more pronounced effects on
medulloblastoma cell responses than in the case of p110β or p110δ, indicating a selective role
for p110α in medulloblastoma [15]. This hypothesis was also confirmed by the observation
that PIK3CA was over-expressed in primary medulloblastoma, compared to normal cerebel-
lum, which was not the case for PIK3CB or PIK3CD [15]. We have previously shown that while
p110δ knock-down by siRNA does not impair cell proliferation in MB, co-targeting p110α and
p110δ led to a greater reduction cell proliferation than single p110alpha targeting [15]. The
precise role of p110δ in MB however remains to be clarified.
In view of these observations, we hypothesized that p110αmay control the expression of a
selective subset of genes implicated in medulloblastoma cell proliferation and/or survival. The
comparative DNA microarray analysis of medulloblastoma cell lines in which either p110α or
p110δ were down-regulated by siRNA identified such a gene subset.
The LIFRα was validated as a downstream target of p110α by a combination of approaches,
including pharmacological inhibition or over-expression of the class IA PI3K isoform. The ob-
servation that LIFRα expression was elevated in the SHH subgroup of primary medulloblasto-
ma, further supports this model, in view of the over-expression of PIK3CA in this subtype.
Importantly, the LIFRα was shown to be functional in medulloblastoma cell lines, since its
activation stimulated classical downstream signaling pathways, such as JAK/STAT, Erk1/2 and
PI3K/Akt. Moreover, the observation that medulloblastoma cell lines generally express LIF
confirms the presence of an autocrine loop in this malignant brain tumor [47]. LIF is a pleio-
tropic cytokine, which can sustain proliferation or differentiation depending on cell type or
maturation [48]. Deregulated LIF secretion has also been previously described in human can-
cer, such as breast cancer, rhabdomyosarcoma and medulloblastoma [47, 49, 50]. In medullo-
blastoma, cell lines, LIF expression was reported to be regulated by p53 [51]. Interestingly, we
have shown a p53-dependent negative regulation of the receptor expression in PTCH-/+ mice
expressing wild type TP53 compared to mice expressing heterozygous TP53. Considering the
previously published LIF dependent negative feedback loop on LIFRα expression [52], the en-
semble of these data strongly suggest an indirect p53-dependent regulation of LIFRα via LIF.
To our knowledge, we performed for the first time in vivo inhibition of LIFRα which let to
tumor volume reduction in CAM assay model. Targeting the LIFRα downstream signaling has
also been evaluated in medulloblastoma. Interfering with STAT3 by using a non-peptide small
molecule STAT3 inhibitor was reported to decrease cell viability and induce apoptosis in me-
dulloblastoma [39]. A study using resveratrol also reported on the importance of STAT3 sig-
naling in maintenance and survival of medulloblastoma cells [53].
There exist so far few reports on the regulation of LIFRα expression and promoter activity.
In breast cancer, c-Myc was shown to act as a negative regulator of LIFRα expression [35]. In
MB, we failed to detect a direct binding of c-Myc to the promoter of the receptor. Nevertheless,
c-Myc-dependent, multiple-partners transcriptional regulation of LIFRα remains plausible.
However, our data support a model in which c-Myc indirectly controls LIFRα protein expres-
sion by repressing miR-125b, a negative regulator of the cytokine receptor. In this regard, re-
cent studies have revealed down-regulation of miR-125b in primary medulloblastoma tumors
compared to normal fetal brain [54]. Furthermore, the LIFRα-dependent proliferation increase
in our MB cell lines, tumor volume reduction upon LIFRα inhibition in vivo and the high
LIFRα expression levels in the SHH subgroup of MB, are supported by data published by Fer-
retti at al. [55] documenting miR-125b-dependent inhibition of cerebellar progenitor prolifera-
tion, via negative regulation of Smoothened, an upstream component in the SHH pathway.
Interestingly, data from Peng et al have described the microRNA as prognosis biomarker in
oral cavity squamous cell carcinoma [56] suggesting strongly the measurement of the circulat-
ing miR-125b also in medulloblastoma. Furthermore, our results suggest PI3K-dependent
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transcriptional regulation of LIFR independently of Myc. Up to date, there are no data describ-
ing direct interaction between the cytokine receptor promoter and a transcription factor.
Previous studies have reported on cross-talks between the PI3K/Akt pathway andmyc-fami-
ly genes. GSK-3β (glycogen synthase kinase 3, isoform β), which is directly regulated by phos-
phorylation through Akt controls Myc phosphorylation and stability [12, 57]. An additional
mechanism of PI3K-dependent regulation of Myc is through PDK1 (Phosphoinositide-depen-
dent kinase-1). The latter phosphorylates PLK1 (Polo-like kinase 1) which in turn induces
MYC phosphorylation at Ser62 and promotes cell growth and survival [58]. In Medulloblasto-
ma, treatment with the PDK1 inhibitor OSU03012 induced apoptosis in vitro and inhibited xe-
nograft tumor growth [4].
In embryonal tumors, including medulloblastoma, targeting the AKT and ERK pathways
using a quassinoid analogue induced c-Myc and N-myc down-regulation [7, 59]. Inhibition of
PI3K using a selective inhibitor was also reported to induce N-myc down-regulation in neuro-
blastoma [60]. N-myc was shown to play an important role in the regulation of PI3K-mediated
VEGF secretion in neuroblastoma cells [61, 62]. Interestingly,MYCN is often found amplified
in SHH type of Medulloblastoma and its expression is linked to poor patient outcome [5, 63].
Recently,MYC amplification has been reported to be implicated in the resistance of tumors
with activated PIK3CA to pharmacological inhibitors of p110α [40, 64].
Together our results delineate a novel signaling pathway from p110α to c-Myc, mir-125b
and LIFRα, which contributes to key medulloblastoma cell responses and may be further
studied to develop novel targeted therapies for this common and devastating childhood
malignancy.
Supporting Information
S1 Fig. LIFR expression in primary brain tumors. LIFR gene expression profile in different
cohorts of atypical teratoid/rhabdoid tumour (1), classic (2) and desmoplastic (3) medulloblas-
tomas, glioblastoma (4) and primitive neuroectodermal tumor (5) compared to normal cere-
bellum (0). Due to large variations in sample sizes, statistical analysis was not performed. The
fold changes (FC) in expression are listed as a reference for this analysis (FC Malignant Glioma =
1.53, FC Desmoplastic Medulloblastoma = 1.3, FC Classic Medulloblastoma = 1.19, FC AT/RT = -1.8). Data
were analyzed with www.oncomine.org, based on Pomeroy et al (27).
(TIF)
S2 Fig. Expression of LIFR and PIK3CA in primary medulloblastoma subtypes. Expression
of PIK3CA and LIFR derived from the transcriptomic analysis of primary medulloblastoma,
grouped according to molecular disease variants. Data from Kool et al. (28) are shown.
(TIFF)
S3 Fig. LIFRα expression in mouse-driven model of SHHmedulloblastoma.Microarray
analysis of LIFRα expression in murine PTCH+/- p53+/- cancer stem cells compared to PTCH
+/- p53+/+ cells (Data set GEO accession number GSE37316). Volcano plot of fold changes
(log2 scale) versus p values (-1log10 scale, grey) and adjusted p values (-log10 scale, pink) is
shown. Highlighted in red are the values for various probe sets representing LIFR.
(TIF)
S4 Fig. LIFRα signaling in medulloblastoma. Cell lysates of DAOY cells stimulated with
oncostatin M (OSM) for 10 min were analyzed for expression and phosphorylation of the indi-
cated OSM downstream targets.
(TIFF)
PI3K Signaling Controls LIFR in Medulloblastoma
PLOSONE | DOI:10.1371/journal.pone.0123958 April 27, 2015 16 / 20
S1 Table. List of PI3K-p110α regulated genes in DAOY cells. List of a gene set deregulated
upon PIK3CA silencing in DAOY cells.
(TIFF)
S2 Table. List of PI3K-p110δ regulated genes in DAOY cells. List of a gene set deregulated
upon PIK3CD silencing in DAOY cells.
(TIFF)
S3 Table. Analysis of transcriptional networks by GeneGo Metacore.Hit list of the tran-
scription factors whose gene networks were mostly affected by the RNAi mediated downregu-
lation of PIK3CA and PIK3CD in DAOY cells.
(TIF)
S4 Table. Genes involved in c-Myc transcriptional network. Fold changes in the gene expres-
sion of predicted c-Myc target genes in DAOY cells transfected with the indicated siRNAs (tar-
geting PIK3CA or PIK3CD) versus control siRNA are listed.
(TIFF)
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